Alcon Vigamox for conjunctivitis
This article was originally published in Pharmaceutical Approvals Monthly
Executive SummaryAlcon receives approval April 15 for its ophthalmic antibiotic Vigamox (moxifloxacin ophthalmic solution 0.5%) for treatment of bacterial conjunctivitis. The fluoroquinolone antibiotic received a priority review. Alcon says that moxifloxacin's high solubility allows for formulation at a higher concentration than other fourth generation fluoroquinolones. The firm also is touting the agent's "near-neutral pH, resulting in a low incidence of [ocular] stinging." Launch is expected in Ma
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.